Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cleveland Biolabs (CBLI)

Cleveland Biolabs (CBLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 49,068
  • Shares Outstanding, K 15,479
  • Annual Sales, $ 260 K
  • Annual Income, $ -2,400 K
  • 60-Month Beta 0.70
  • Price/Sales 201.29
  • Price/Cash Flow N/A
  • Price/Book 3.62
Trade CBLI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 08/16/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview

Details
  • Implied Volatility 0.00%
  • Historical Volatility 113.24%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +17.41%
on 08/16/21
4.23 -25.06%
on 08/02/21
-1.13 (-26.28%)
since 07/30/21
3-Month
2.70 +17.41%
on 08/16/21
7.10 -55.35%
on 07/06/21
-2.23 (-41.30%)
since 05/28/21
52-Week
1.62 +95.68%
on 09/04/20
10.97 -71.11%
on 02/18/21
+1.29 (+68.62%)
since 08/28/20

Most Recent Stories

More News
Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."

/PRNewswire/ --  (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced plans to change its corporate...

CBLI : 3.17 (-7.31%)
STAB : 3.21 (-1.23%)
Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast

/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the audio archive...

CBLI : 3.17 (-7.31%)
Cytocom, Inc. Reports Second Quarter 2021 Financial Results

/PRNewswire/ --  (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported...

CBLI : 3.17 (-7.31%)
Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement

/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced a collaboration agreement...

CBLI : 3.17 (-7.31%)
Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate...

CBLI : 3.17 (-7.31%)
Cytocom, Inc. to Report Second Quarter 2021 Financial Results

/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will...

CBLI : 3.17 (-7.31%)
Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

/PRNewswire/ --   (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding...

CBLI : 3.17 (-7.31%)
Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

/PRNewswire/ --  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update...

CBLI : 3.17 (-7.31%)
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

/PRNewswire/ -- , (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for in committed capital. The financing...

CBLI : 3.17 (-7.31%)
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs

/PRNewswire/ -- Cytocom Inc. ("Cytocom" or "Company"), a leading biopharmaceutical company creating next-generation therapies that focus on immune homeostasis, today announced the completion of its merger...

CBLI : 3.17 (-7.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Cytocom Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Cytocom Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 3.83
2nd Resistance Point 3.68
1st Resistance Point 3.42
Last Price 3.17
1st Support Level 3.01
2nd Support Level 2.86
3rd Support Level 2.60

See More

52-Week High 10.97
Fibonacci 61.8% 7.40
Fibonacci 50% 6.30
Fibonacci 38.2% 5.19
Last Price 3.17
52-Week Low 1.62

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar